Mitochondrial dysfunction in human hypertrophic cardiomyopathy is linked to cardiomyocyte architecture disruption and corrected by improving NADH-driven mitochondrial respiration

Author:

Nollet Edgar E12ORCID,Duursma Inez12ORCID,Rozenbaum Anastasiya12,Eggelbusch Moritz345ORCID,Wüst Rob C I3ORCID,Schoonvelde Stephan A C6ORCID,Michels Michelle6ORCID,Jansen Mark7ORCID,van der Wel Nicole N8ORCID,Bedi Kenneth C9ORCID,Margulies Kenneth B9ORCID,Nirschl Jeff10,Kuster Diederik W D12ORCID,van der Velden Jolanda12ORCID

Affiliation:

1. Department of Physiology, Amsterdam UMC , Location VUmc, O2 Science building—11W53, De Boelelaan 1108, 1081HZ Amsterdam , The Netherlands

2. Amsterdam Cardiovascular Sciences, Heart failure & Arrhythmias, Amsterdam UMC , Location VUmc, O2 Science building, De Boelelaan 1108, 1081 HZ Amsterdam , The Netherlands

3. Laboratory for Myology, Faculty of Behavioural and Movement Sciences, Amsterdam Movement Sciences, Vrije Universiteit Amsterdam , Amsterdam , The Netherlands

4. Department of Nutrition and Dietetics, Amsterdam UMC , Amsterdam , The Netherlands

5. Faculty of Sports and Nutrition, Center of Expertise Urban Vitality, Amsterdam University of Applied Sciences , Amsterdam , The Netherlands

6. Department of Cardiology, Erasmus MC , Rotterdam , The Netherlands

7. Division of Genetics, UMC Utrecht , Utrecht , The Netherlands

8. Department of Medical Biology, Electron Microscopy Centre, Amsterdam UMC , Amsterdam , The Netherlands

9. Cardiovascular Institute, Perelman School of Medicine , Philadelphia, PA , USA

10. Department of Pathology, Stanford University , Stanford , USA

Abstract

AbstractAimsGenetic hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomere protein-encoding genes (i.e. genotype-positive HCM). In an increasing number of patients, HCM occurs in the absence of a mutation (i.e. genotype-negative HCM). Mitochondrial dysfunction is thought to be a key driver of pathological remodelling in HCM. Reports of mitochondrial respiratory function and specific disease-modifying treatment options in patients with HCM are scarce.Methods and resultsRespirometry was performed on septal myectomy tissue from patients with HCM (n = 59) to evaluate oxidative phosphorylation and fatty acid oxidation. Mitochondrial dysfunction was most notably reflected by impaired NADH-linked respiration. In genotype-negative patients, but not genotype-positive patients, NADH-linked respiration was markedly depressed in patients with an indexed septal thickness ≥10 compared with <10. Mitochondrial dysfunction was not explained by reduced abundance or fragmentation of mitochondria, as evaluated by transmission electron microscopy. Rather, improper organization of mitochondria relative to myofibrils (expressed as a percentage of disorganized mitochondria) was strongly associated with mitochondrial dysfunction. Pre-incubation with the cardiolipin-stabilizing drug elamipretide and raising mitochondrial NAD+ levels both boosted NADH-linked respiration.ConclusionMitochondrial dysfunction is explained by cardiomyocyte architecture disruption and is linked to septal hypertrophy in genotype-negative HCM. Despite severe myocardial remodelling mitochondria were responsive to treatments aimed at restoring respiratory function, eliciting the mitochondria as a drug target to prevent and ameliorate cardiac disease in HCM. Mitochondria-targeting therapy may particularly benefit genotype-negative patients with HCM, given the tight link between mitochondrial impairment and septal thickening in this subpopulation.

Funder

Netherlands Organization for Scientific Research

Leducq Foundation

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Reference72 articles.

1. New perspectives on the prevalence of hypertrophic cardiomyopathy;Semsarian;J Am Coll Cardiol,2015

2. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines;Ommen;J Am Coll Cardiol,2020

3. Clinical course and management of hypertrophic cardiomyopathy;Maron;N Engl J Med,2018

4. Genetic advances in sarcomeric cardiomyopathies: state of the art;Ho;Cardiovasc Res,2015

5. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM registry;Neubauer;J Am Coll Cardiol,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3